Although management guidelines for LAM are mostly based upon studies of sporadic LAM [25–27], the similar disease manifestations of TSC-LAM suggest that their use in TSC is appropriate; particularly recommendations for mTOR inhibitor therapy and early surgical treatment for pneumothorax [26, 27]. The gene discussed is MTOR; the disease is lymphangioleiomyomatosis.